Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation
Journal of Assisted Reproduction and Genetics · 2024
DOI: 10.1007/s10815-024-03214-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Assisted Reproduction and Genetics, 2024. Verfasst von Atoosa Ghofranian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, Department of Obstetrics, Gynecology and Reproductive Science, New York, NY, USA. atoosagmd@gmail.com. Hauptthemen laut MEDLINE: Spironolactone, Ovulation Induction, Oocytes, Oocyte Retrieval. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
PURPOSE: To evaluate the association between spironolactone use and controlled ovarian hyperstimulation (COH) outcomes. METHODS: Retrospective study, including patients who underwent COH. Oocyte yield and maturation rates were compared by categories of spironolactone use at the start of their cycle. RESULTS: 402 patients were included. 83 patients continued spironolactone, 44 patients discontinued spironolactone, and 275 matched control patients were spironolactone-naïve. No difference was observed in the number of oocytes retrieved (17 ± 14 vs. 15 ± 13, p = 0.4) or mature oocytes vitrified (15 ± 9.5 vs. 12 ± 11, p = 0.4) in patients who continued spironolactone use and spironolactone naïve patients, respectively. When comparing patients who continued spironolactone use and patients who discontinued spironolactone use, no difference was seen in the number of oocytes retrieved (17 ± 14 vs. 17.5 ± 7.8, p = 0.9) or mature oocytes vitrified (15 ± 9.5 vs. 13.5 ± 6.5, p = 0.5), respectively. There was no observed relationship between total daily spironolactone dose ( 200 mg/day) and the total number of mature oocytes vitrified (respectively, 14.0 ± 13.0, 16.0 ± 7.8, 14.0 ± 4.5, 11.0 ± 7.0 oocytes, p = 0.4). CONCLUSIONS: This is the first study to evaluate the association between spironolactone and oocyte yield and maturation rates during COH cycles. These findings can assist in counseling patients on the implications of continuing spironolactone during COH cycle.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, Department of Obstetrics, Gynecology and Reproductive Science, New York, NY, USA. atoosagmd@gmail.com.
- Icahn School of Medicine at Mount Sinai, Department of Obstetrics, Gynecology and Reproductive Science, New York, NY, USA.
- Reproductive Medicine Associates of New York, 635 Madison Avenue, 11th Floor, New York, NY, 10022, USA.
Förderung
- NCATS NIH HHS
Zitieren
APA
Ghofranian, A., Estevez, S. L., Dubois, B., Gellman, C., Gounko, D., Lee, J. A., Copperman, A. B., & Thornton, K. (2024). Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics. https://doi.org/10.1007/s10815-024-03214-6
Vancouver
Ghofranian A, Estevez SL, Dubois B, Gellman C, Gounko D, Lee JA, et al. Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics. 2024. doi:10.1007/s10815-024-03214-6
BibTeX
@article{Ghofranian2024,
author = {Ghofranian, Atoosa and Estevez, Samantha L and Dubois, Bethany and Gellman, Caroline and Gounko, Dmitry and Lee, Joseph A and Copperman, Alan B and Thornton, Kimberly},
title = {Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation},
journal = {Journal of Assisted Reproduction and Genetics},
year = {2024},
doi = {10.1007/s10815-024-03214-6}
}
EUVIMED